Legal headwinds alongside M&A moves and new plants

Johnson & Johnson is juggling mounting legal pressure while simultaneously reshaping its portfolio and manufacturing network. The company faces a fresh talc verdict and a new false-advertising lawsuit from Bayer over prostate cancer drug marketing, underscoring ongoing liability risk. At the same time, J&J is divesting assets like NeuWave Medical to Quantum Surgical, and deepening its manufacturing footprint through a new $1B+ cell therapy plant in Pennsylvania and tenancy at Fujifilm Diosynth’s $2B Holly Springs biologics site. Together, these shifts highlight J&J’s strategy to streamline its business and scale advanced therapies amid persistent legal challenges.